Trial reportAlcoholism, clinical and experimental research2021
Ibudilast attenuates alcohol cue-elicited frontostriatal functional connectivity in alcohol use disorder.
Trial report in Alcoholism, clinical and experimental research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03489850 (Withdrawal-Related Dysphoria as a Moderator of Ibudilast for Alcohol Use Disorder), which is not on this map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Withdrawal-Related Dysphoria as a Moderator of Ibudilast for Alcohol Use Disorder
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Cue-Elicited Brain Activity and Treatment Outcomes in Substance Use Disorders: A Meta-Analysis.JAMA network open · 2025Pooled it
- GenomeMUSter mouse genetic variation service enables multitrait, multipopulation data integration and analysis.Genome research · 2024Pooled it
- A meta-analysis of the neural substrates of monetary reward anticipation and outcome in alcohol use disorder.Human brain mapping · 2023Pooled it
- Baseline C-reactive protein levels are predictive of treatment response to a neuroimmune modulator in individuals with an alcohol use disorder: a preliminary study.The American journal of drug and alcohol abuse · 2023Trial
- Pain Catastrophizing Is Associated With Increased Alcohol Cue-Elicited Neural Activity Among Individuals With Alcohol Use Disorder.Alcohol and alcoholism (Oxford, Oxfordshire) · 2022Trial
- Towards Mechanism-Informed Treatments for Mental Health.Journal of neurochemistry · 2026Review
- Bridging Inflammation and Oncology: The Role and Therapeutic Potential of Macrophage Migration Inhibitory Factor in Lung Cancer.International journal of molecular sciences · 2026Review
- Task-related differences in network connectivity and dynamics in people with severe opioid use disorder compared with healthy controls.Translational psychiatry · 2026Article
- The Impaired Response Inhibition and Salience Attribution Model of Drug Addiction: Recent Neuroimaging Evidence and Future Directions.Annual review of psychology · 2026Review
- Apremilast reduces co-occurring alcohol drinking and mechanical allodynia and regulates central amygdala GABAergic transmission.JCI insight · 2025Article
- Central amygdala neuroimmune signaling in alcohol use disorder.Addiction neuroscience · 2025Article
- Macrophage migration inhibitory factor (MIF) in CNS diseases: Functional regulation and potential therapeutic indication.Fundamental research · 2024Review
- Generalized genetic liability to substance use disorders.The Journal of clinical investigation · 2024Review
- Promising immunomodulators for management of substance and alcohol use disorders.Expert opinion on pharmacotherapy · 2024Review
- Sex-dependent factors of alcohol and neuroimmune mechanisms.Neurobiology of stress · 2023Article
- Chronic ethanol induces a pro-inflammatory switch in interleukin-1β regulation of GABAergic signaling in the medial prefrontal cortex of male mice.Brain, behavior, and immunity · 2023Article
- Multivariate genome-wide association meta-analysis of over 1 million subjects identifies loci underlying multiple substance use disorders.Nature. Mental health · 2023Article
- The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2023Article
- Cyclic Nucleotide Phosphodiesterases in Alcohol Use Disorders: Involving Gut Microbiota.The international journal of neuropsychopharmacology · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundIbudilast, a novel neuroimmune modulator being studied to treat alcohol use disorder (AUD), was shown in a randomized controlled trial (NCT03489850) to reduce ventral striatum (VS) activation in response to visual alcohol cues. The present study extended this finding by probing the effects of ibudilast on alcohol cue-elicited functional connectivity (i.e., temporally correlated activation) with the VS seed. The study also tests the association between functional connectivity and alcohol use during the trial.
methodsNon-treatment-seeking participants (n = 45) with current alcohol use disorder were randomized to receive twice-daily dosing with either ibudilast (50 mg; n = 20) or placebo (n = 25). Upon reaching the target dosagee of the medication or placebo, participants completed a functional neuroimaging alcohol cue reactivity paradigm. Drinks per drinking day were assessed at baseline and daily during the 2-week trial.
resultsIbudilast reduced alcohol cue-elicited functional connectivity between the VS seed and reward-processing regions including the orbitofrontal and anterior cingulate cortices compared with placebo (p < 0.05). Cue-elicited functional connectivity was correlated with drinks per drinking day (R
conclusionsIbudilast's effects on drinking outcomes may be related to the attenuation of functional connectivity in frontostriatal circuits related to reward processing. These results provide an important proof of concept for this novel pharmacotherapy and support the clinical utility of incorporating neuroimaging-and especially functional connectivity-analyses into medication development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.